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Respiratory  syncytial  virus  (RSV)  is  the  leading  cause  of  bronchiolitis  and viral  pneumonia  in infants  and
young  children  worldwide.  In  the  Middle  East  and  Arab  countries,  the  burden  of RSV-associated  hospi-
talizations  is  not  well  characterized.  We  sought  to determine  the burden  and  clinical/epidemiological
characteristics  of RSV hospitalization  in  young  children  in  Amman,  Jordan.  We investigated  risk  factors
for  severity  including  vitamin  D levels.
Methods:  We  conducted  viral  surveillance  with  clinical  and  demographic  data  in  children  <2  years  admit-
ted  with  respiratory  symptoms  and/or  fever  at the  Al-Bashir  Government  Hospital  from  March16,  2010
to  March  31,  2013.  Nasal/throat  swabs  were  obtained  and  placed  into  lysis  buffer,  and  frozen  at  −80 ◦C
until  testing  by real-time  RT-PCR  for  11  respiratory  viruses.  Heel  stick  blood  or sera samples  for  25-
hydroxyvitamin  D [25(OH)D]  levels  were  obtained  and  sent  to  a central  laboratory  for mass  spectrometry.
Results:  Of  the 3168  children,  >80%  testing  positive  for one  virus,  with  RSV  the  most  common  virus
detected  (44%).  The  RSV-associated  hospitalization  rate  was highest  in  children  <6  months  with  an  annual
range  of  21.1–25.9  per  1000,  compared  to 6.0–8.0  in  6–11-month-olds  and 1.6–2.5 in  12–23-month-olds.
RSV-positive  children  compared  with  RSV-negative  were  more  likely  to be  previously  healthy  without
underlying  medical  conditions,  less  likely  to  be  born  prematurely,  had a  higher  frequency  of supplemental
oxygen  use,  and had  lower  median  vitamin  D  levels.  Risk  factors  for oxygen  use  in RSV-positive  children
included  underlying  medical  conditions,  lack  of  breastfeeding,  younger  age,  and higher viral  load.
Conclusion:  RSV  is a major  cause  of  illness  in  hospitalized  Jordanian  children  and  is associated  with
increased  severity  compared  to  other  respiratory  viruses.  Children  with  RSV  in  the  Middle  East would
beneﬁt  from  future  RSV  vaccines  and  antiviral  therapy.
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1. Introduction
Respiratory syncytial virus (RSV) is the leading cause of bronchi-
olitis and viral pneumonia in infants and young children worldwide
[1]. A global incidence estimate for RSV-associated acute respira-
tory infections (ARI) in children <5 years in 2005 suggests 33.8
million new episodes of RSV-associated ARI with at least 3.4 mil-
lion episodes necessitating hospital admission [2]. An estimated
66,000–190,000 children died from RSV-associated ARI, and 99%
of these deaths occurred in developing countries, though the Mid-
dle East was not considered due to paucity of published data [2].
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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peciﬁcally, very few population-based viral surveillance studies,
ncluding determining burden of RSV disease, have been performed
n the Middle East, and few of these have used highly sensitive
olecular techniques such as real-time reverse-transcriptase poly-
erase chain reaction [3–13]. Also, many of these studies had small
amples sizes and the duration of the study period was usually for
nly one respiratory season. Thus, the true prevalence and burden
f RSV disease in the Middle East remains unknown.
Recognizing that the viral etiology of ARI among Middle Eastern
hildren in Arab countries was poorly characterized, in 2007 we
ad conducted a pilot viral surveillance study in children <5 years
dmitted with respiratory symptoms and/or fever at two hospitals
n Amman, Jordan over a three-month winter period [14–16]. Of the
28 subjects enrolled, >80% tested positive for a virus by RT-PCR,
ith 64% testing positive for RSV. Compared to RSV-negative sub-
ects, the RSV-positive subjects had lower median age, higher rates
f oxygen use, longer hospital stay, and higher hospital charges.
hese pilot data suggested that in young hospitalized Jordanian
hildren, the medical and ﬁnancial burden of RSV was  high. To
ore deﬁnitively address the burden of RSV disease in the present
tudy, we conducted a three-year viral surveillance in Amman, Jor-
an and limited the age group to children <2 years, the age group
epresenting >90% of the cases in our 2007 pilot study.
. Methods
.1. Study design
We  conducted a prospective, year-round viral surveillance study
nrolling children <2 years with respiratory symptoms and/or fever
ithin 48 h of hospital admission at Al-Bashir Hospital, the major
overnment-run referral center in Amman, Jordan. Children were
nrolled ﬁve days a week (Sunday through Thursday) if they pre-
ented with a history of fever and/or respiratory symptoms and one
f the following admission diagnoses: ARI, apnea, asthma exac-
rbation, bronchiolitis, bronchopneumonia, croup, cystic ﬁbrosis
xacerbation, febrile seizure, fever without localizing signs, respi-
atory distress, pneumonia, pneumonitis, pertussis, pertussis-like
ough, rule out sepsis, upper respiratory infection (URI), or other.
hildren were excluded only if they had chemotherapy-associated
eutropenia and/or were newborns who had never been dis-
harged.
Written informed consent was obtained from parents or
uardians before enrollment into the study. The institutional
eview boards at the University of Jordan, the Jordanian Ministry of
ealth, and Vanderbilt University approved the study.
.2. Study location
Al-Bashir Hospital is one of three major government-run referral
edical centers that serve the population of Amman, which is esti-
ated to be >2 million. With its 185 pediatric beds (120 pediatric
nd 65 neonatal intensive care unit), the Ministry of Health esti-
ates that during the study period, the Al-Bashir Hospital provided
are for at least 50–60% of children in Amman  (author SF, personal
ommunication). Al-Bashir provides care to government employ-
es and their dependents, underprivileged families in Amman, and
atients who are referred from other health care centers in Jor-
an [17]. It is located in the low-income and densely populated
l-Ashraﬁeh area of eastern Amman, which includes the nearby
l Wihdat Palestinian refugee camp. Patients with ﬁnancial con-
traints are also admitted to this hospital since Jordan adopted a
olicy of providing no-cost medical care to children <6 years at
overnment-run institutions regardless of insurance status. Dur-
ng the 3-year study period, there were 17,557 hospitalizations (2015) 6479–6487
admitted to the pediatric wards, 11,230 (64%) among children <2
years.
2.3. Data and specimen collection
Trained research staff obtained nasal and throat swabs from all
enrolled children. If permission was  granted, staff also obtained
blood by a heel stick or venipuncture. Demographic characteristics
and medical and social histories were obtained using standardized
questionnaires; parents were queried in Arabic and the informa-
tion was recorded in English. The medical charts were abstracted
after discharge; demographic, epidemiologic, and clinical data were
collected systematically. Vital signs at admission were recorded by
clinicians. Oxygen saturations were collected as ranges:95–100%,
90–94%, 85–89%, and <85%. Flaring or retractions were catego-
rized as none, mild (ﬂaring only), moderate (retractions), or severe
(accessory muscle use). Wheezing on physical exam was  catego-
rized as none, end-expiratory, full expiratory or inspiratory, full
expiratory and inspiratory, or not speciﬁed. Cyanosis was recorded
as none, circumoral on crying only, circumoral at rest, generalized
cyanosis at rest, or not speciﬁed. Documentation of microbiolog-
ical data was obtained and viral identiﬁcation laboratory results
were recorded. Intensive care unit (ICU) stays included children
who were either admitted directly to the ICU or were transferred
in during the admission. Smoke exposure included both cigarette
and/or nargalia (hookah pipe) exposure. Underlying conditions
were collected and were categorized as the following: diabetes,
heart disease, down’s syndrome, kidney disease, sickle cell, cys-
tic ﬁbrosis, cancer, genetic/metabolic, cerebral palsy, neurological,
mental retardation/developmental delay, seizure disorder, chronic
diarrhea(e.g. >2 weeks), gastroesophageal reﬂux disease, immu-
nodeﬁciency, asthma/reactive airway disease, and liver disease.
We entered data into a standardized, secured REDCapTM (Research
Electronic Data Capture, Vanderbilt University, Nashville, TN, USA)
database system [18]. Data quality checks were performed on at
least 10% of the charts and all case report forms were veriﬁed after
entry.
2.4. Classiﬁcation
To better understand the role of RSV in pediatric lower respira-
tory tract infection (LRTI), we identiﬁed a sub-cohort of children.
The LRTI cohort consisted of children with an admission diagnosis
of asthma, bronchiolitis, bronchopneumonia, pneumonia, respi-
ratory distress, or wheezing; or clinical signs of retractions or
accessory muscle use; or wheezing on examination.
2.5. Laboratory testing
Nasal and throat swabs were collected and combined
in transport medium (M4RT®, Remel, USA), aliquoted into
MagMAXTMLysis/Binding Solution Concentrate (Life Technologies,
USA), snap frozen, and stored at −80 ◦C. Original and lysis buffer
aliquots were shipped on dry ice and were tested by RT-PCR for
eleven respiratory viruses (RSV, human metapneumovirus (HMPV),
human rhinovirus (HRV), inﬂuenza (ﬂu) A and B, C, and parain-
ﬂuenza (PIV) virus 1, 2, and 3, adenovirus (adeno), and Middle East
respiratory syndrome coronavirus (MERS-CoV) [19–25,15,26,27].
2.6. Vitamin D testingBlood was placed directly onto ﬁlter paper and air dried for
≥30 min  before storage at room temperature and kept in a dry state
until shipment to ZRT Laboratory (Beaverton, OR,  USA) for vitamin
D assay per protocol [28,29–33].
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.7. Statistical analysis
Descriptive statistics were presented as frequency (percentage)
r median and interquartile range (IQR) where appropriate. Cat-
gorical variables were compared using Pearson Chi-square test.
ontinuous variables were compared using Mann-Whitney U test.
or ≥3 groups comparison of continuous variables, Kruskal–Wallis
est was used. We  ﬁt a multivariable logistic model to analyze the
isk of oxygen use, ICU stay, mechanical ventilation, and length of
tay as indicators for severity. The risk factors assessed included
reastfeeding, vitamin D level, age at enrollment, gestational age,
irth weight, gender, past medical history, smoke exposure, day-
are, the four most common admission diagnoses (pneumonia,
ronchopneumonia, bronchiolitis, and suspected sepsis) and RSV
ount. Daycare was removed from the ICU model because there
ere not subjects who were admitted to the ICU who attended
aycare. All analyses were performed using statistical software R
ersion 3.1.2 (http://www.R-project.org/).
The enrolled sample was used to provide model-based estimates
revalence of RSV. The data were ﬁltered to exclude admissions
f individuals not residing in Amman. We  used a Bayesian hierar-
hical model to derive prevalence estimates for each of the three
ears of the study [20]. In order to derive prevalence, estimates of
he under 2-year-old Jordanian population were obtained from the
orld Bank online database, and the proportion of the population
esiding in Amman  (35%) was taken from the 2012 national census
21]. These values were used in a binomial model to estimate the
opulation of children <2 years of age in Amman  in 2010-2012. The
arket share for Al-Bashir hospital was modeled as a random vari-
ble, and given a uniform prior distribution between 50 and 60%
f the market share. Finally, to account for the enrollment effort,
he probability of enrollment was set to 71.4% (5 of 7 days) and
sed in a binomial model for the number enrolled in the study.
revalence was given a diffuse beta (1,5) prior in all models. Each
odel was ﬁtted using Markov chain Monte Carlo [22] methods
s implemented in the PyMC 2.3 software package [23]. Models
ere run for 100,000 iterations, with the ﬁrst 90,000 iterations
onservatively discarded as burn-in. Models were checked for con-
ergence using the Gelman-Rubin diagnostic [20] and for goodness
f ﬁt using posterior predictive checks [24].
Fig. 1. The frequency of RSV-positive hospitalized children over the th (2015) 6479–6487 6481
3. Results
3.1. Study population
From March 16, 2010 to March 31, 2013, 3793 patients were eli-
gible, of whom 3175 (83.7%) were enrolled. Seven patients (0.2%)
were excluded: three were ≥2 years and four had the admission
diagnosis of meningitis. Thus, 3168 subjects (83.5% of eligible sub-
jects) were included in the ﬁnal cohort.
3.2. Clinical and demographic characteristics of entire
surveillance cohort
The median age was 3.5 months (range 0.06–23.64 months),
with 31% of the children <2 month, 34% 2–5 months, 20% 6–11
months (total 85% <1 year) and 15% 12–23 months. Sixty percent
were male. Nearly 90% of the children had Jordanian parents, 7%
Palestinian, and 3% other. By medical chart reviews or parent histo-
ries, 11.8% of the children were noted to have an underlying medical
condition and 14% of the children had a history of prematurity
(<37 weeks). Prior to hospitalization, 41% received an antibiotic
and nearly the entire cohort (92%) were administered an antibi-
otic during their hospital stay. Almost 93% of the children had one
of ﬁve admission diagnoses: bronchopneumonia (32%), suspected
sepsis (29%), bronchiolitis (17%), pneumonia (12%), and pertussis-
like cough (7%). We  had vitamin D levels for 2688 (85%) children;
the median vitamin D level was 16.5 ng/mL.
3.3. Viral detection
All 3168 children had a nasopharyngeal swab obtained. A virus
was detected in 81% of the children. The most common virus
detected was RSV (44%), followed by HRV (39%), adeno (15%), HMPV
(9%), PIV 1, 2, and 3 (6%), and Flu A, B and C(4%). MERS-CoV was
not detected. Fig. 1 includes the frequency and distribution of RSV
over a three-year period, with peaks in January and February. Of
the 1397 RSV-positive children, 669 (48%) had at least one other
virus detected and Fig. 2 illustrates the combination of these co-
infections.
ree-year study period (March 16, 2010 through March 31, 2013).
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Fig. 2. The percent of RSV-positive only a
Table 1
Estimated Rates of RSV Hospitalizations with 95% credible intervals by year and by
age groups per 1000 persons.
<6 months 6–11 months 12–23 months
Year 1
(03/16/2010–3/31/2011)
21.1 (17.9, 24.4) 6.8 (5.4, 8.4) 1.6 (1.1, 2.1)
Year 2
(04/01/2011–3/31/2012)
23.5 (19.8, 26.8) 6.0 (4.7, 7.5) 2.3 (1.7, 2.9)
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aYear 3
(04/01/2013–3/31/2013)
25.9 (22.0, 29.4) 8.0 (6.5, 9.9) 2.5 (1.9, 3.2)
.4. RSV hospitalization rates
Using Jordanian census data and restricting our cohort to chil-
ren who resided in Amman, we were able to estimate RSV
ospitalization rates for each study year (Table 1). Of the 3168
hildren, 3048 (96.2%) resided in Amman. The RSV rates were
ubstantially higher in children <6 months (21.1–25.9 per 1000)
ompared to the older age groups: 6–8 per 1000 in 6–11-month-
lds and 1.6–2.5 per 1000 in children ages 12–23 months.
.5. Clinical and demographic characteristics comparing
SV-positive to RSV-negative children
A comparison of RSV-positive children compared to RSV-
egative is shown in Table 2. RSV-positive children were more
ikely to have been previously healthy, with no signiﬁcant underly-
ng medical condition, and were less likely to be born prematurely
Table 2). RSV-positive subjects were also more likely to have the
iagnoses of bronchiolitis, bronchopneumonia, pneumonia, and
ertussis-like cough compared to RSV-negative children (Table 2).
hen comparing presenting symptoms as reported by parents,
SV-positive children were more likely to present with cough and
hortness of breath and less likely to present with fever, decreased
ctivity, diarrhea, or vomiting (Table 2).
The RSV-positive children were more likely to have a physician
ocument wheezing, cyanosis, and abnormal ﬂaring and retrac-
ions on exam and an abnormal chest radiograph (Table 2). These
hildren had a comparatively higher frequency of supplemental
xygen use, were more likely to have <90% oxygen saturation at
dmission (9% vs. 6% for RSV-negative children, p < 0.01), and werend RSV-positive with co-detection.
less likely to have oxygen saturation >95% (36% vs. 42%, p < 0.01).
The RSV-positive children also had lower median vitamin D levels
(Table 2). The mortality rate was  lower in the RSV-positive chil-
dren, (0.5% vs. 1%, p = 0.015). In order to understand if co-infection
with another virus was  associated with increased severity, we com-
pared RSV-only children with RSV co-infected children. RSV-only
children had slightly higher percentage of cough reported prior to
admission 96% vs. 93% (p < 0.01), were more likely to report a runny
nose/congestion (3% vs. 1%, p = 0.01), and had comparable severity
of disease.
3.6. Clinical characteristics of children with lower respiratory
tract infection
In order to characterize the features of RSV-associated LRTI, we
analyzed the subset of children who  presented with LRTI. Of the
3168 children, 2263 (71.4%) met  criteria for LRTI. Of these, 1210
(53.5%) had RSV, 785 (34.7%) had another virus detected, and 268
(11.8%) had no virus detected (Table 3). Children with RSV were
more likely to be younger, have a history of breastfeeding, have
the diagnoses of bronchiolitis or pertussis-like cough, present with
cough or shortness of breath, and have cyanosis on exam com-
pared to other virus-positive and virus-negative children (Table 3).
In addition, they were more likely to require oxygen and had lower
median vitamin D levels (Table 3). Children who  had virus-negative
LRTI were more likely to have an underlying medical condition, be
admitted to the ICU, and die compared to the other groups (Table 3).
3.7. Risk factors for illness severity: Oxygen use, ICU stay,
mechanical ventilation, and length of stay
To assess for severity of illness indicators, we compared the
following outcomes in RSV-positive children: oxygen require-
ment, any ICU stay, mechanical ventilation, and length of stay
(Tables 4 and 5) in a univariate and/or multivariable analyses. Lack
of breastfeeding, lower age, and higher viral load (indicated by
lower Ct values) were associated with oxygen use, while the diag-
noses of bronchiolitis, suspected sepsis, and bronchopneumonia
were not associated (Table 4). The diagnoses of pneumonia and sus-
pected sepsis and lower age were more likely to be associated with
ICU stay but less likely with the diagnosis of bronchopneumonia
N. Halasa et al. / Vaccine 33 (2015) 6479–6487 6483
Table  2
Clinical and demographic comparisons of RSV-positive and RSV-negative children.
Total N = 3168 RSV-positive N = 1397 RSV-negative N = 1771 p-Value
Age (months) median 3.5 months 3.5 months 0.16
0–1  months 135 (10%) 248 (14%) <0.01
2–5  months 736 (53%) 772 (44%)
6–11  months 327 (23%) 394 (22%)
12–23 months 199 (14%) 357 (20%)
Sex  (male) 834 (60%) 1078 (61%) 0.50
Daycare** 27 (2%) 23 (1%) 0.16
Breastfeeding 1200 (86%) 1461 (82%) 0.01
No  past medical history 1286 (92%) 1507 (85%) <0.01
Smoke exposure 1070 (77%) 1355 (77%) 0.96
Antibiotics prior to
hospitalization
653 (47%) 633 (36%) <0.01
Antibiotics during
hospitalizationa
1279 (92%) 1612 (92%) 0.61
Gestational
Age
Median % < 37 weeks
179 (13%) 271 (15%) 0.046
Birth  weight (median, kg)• 3.0 3.0 0.074
Admission diagnosis
Bronchiolitis 374 (27%) 173 (10%) <0.01
Bronchopneumonia 476 (34%) 544 (31%) 0.045
Pneumonia 225 (16%) 169 (10%) <0.01
Suspected sepsis 248 (18%) 664 (37%) <0.01
Pertussis-like cough 129 (9%) 96 (5%) <0.01
Presenting symptoms
Fever 649 (46%) 1113 (63%) <0.01
Cough  1320 (94%) 1046 (59%) <0.01
Shortness of breath 1039 (74%) 793 (45%) <0.01
Runny nose/congestion 40 (3%) 37 (2%) 0.16
Decrease appetite 301 (22%) 399 (23%) 0.51
Seizures/convulsions 19 (1%) 106 (6%) <0.01
Decrease activity* 77 (20%) 238 (36%) <0.01
Diarrhea 69 (5%) 248 (14%) <0.01
Vomiting 186 (13%) 336 (19%) <0.01
Key  examination ﬁndings
Wheezing 926 (66%) 831 (47%) <0.01
Cyanosis 362 (26%) 258 (15%) <0.01
Flaring/retractions 173 (12%) 108 (6%) <0.01
Abnormal chest X-rayb 1122 (82%) 955 (60%) <0.01
Outcomes
O2  requirementc 566 (41%) 447 (25%) <0.01
Days  on oxygen (25th, 50th,
75th, mean, standard
deviation)
1 2 5 (3.76 ± 3.3) 1 2 4 (3.28 ± 3.1) 0.041
Mechanical ventilationsd 52 (4%) 59 (3%) .54
ICU  staye 126 (9%) 158 (9%) 0.89
Median length of stay (days)f 4 4 0.2
Deathd 7 (0.5%) 24 (1%) 0.015
Vitamin D level (ng/mL)g 14.3 ng/mL 18.2 ng/mL <0.01
a 3147.
b 2961.
c 3137.
d 3136.
e 3140.
f 3139.
g 2688.
 1012.
(
a
w
l
s
(
o
o* n = 1044.
** 3167.
• 3166.
Table 4). Mechanical ventilation was associated with younger age
nd higher vitamin D level (Table 4). The following were associated
ith longer length of stay: having an underlying medical condition,
ack of breastfeeding, the diagnoses of pneumonia and suspected
epsis, younger age, lower gestational age, and higher viral load
indicated by lower Ct values) in contrast, the diagnoses of bronchi-
litis and bronchopneumonia were associated with shorter length
f stay (Table 5).4. Discussion
In our 2010–2013 surveillance window, RSV was a major
cause of ARI hospitalizations in Jordanian children <2 years, with
consistent annual peaks in January and February. Our study repre-
sents one of the largest cohort studies of RSV-infected hospitalized
children, including within the Middle East [10–13,34–43]. RSV is
well-recognized cause of ARI globally [2], but even comprehensive
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Table 3
Clinical and demographic comparisons of lower respiratory tract infection by RSV-positive, other virus-positive, and virus-negative children.
Total Cohort N = 2263 RSV-positive LRTI (N = 1210) Virus other-positive LRTI (N = 785) Virus-negative LRTI (n = 268) p-Value
Age (months) median 4.2 7.1 6.2 <0.01
0–1  months 78 (6%) 30 (4%) 20 (7%) <0.01
2–5  months 618 (51%) 249 (32%) 92 (34%)
6–11  months 320 (26%) 279 (36%) 76 (28%)
12–23 months 194 (16%) 227 (29%) 80 (30%)
Sex  (male) 733 (61%) 484 (62%) 154 (57%) 0.48
Daycarea 26 (2%) 12 (2%) 7 (3%) 0.46
Breastfeeding 1031 (85%) 627 (80%) 211 (79%) 0.002
No  past medical history 1104 (91%) 629 (80%) 207 (77%) <0.01
Smoke exposure 929 (77%) 594 (76%) 213 (79%) 0.44
Antibiotics prior to hospitalization 605 (50%) 371 (47%) 128 (48%) 0.46
Antibiotics during hospitalizationb 1099 (91%) 708 (91%) 236 88%) 0.28
Gestational
Age
Median % < 37 weeks
148 (12%) 127 (16%) 41 (15%) 0.04
Birth  weight (kg)c (25th, 50th, 75th,
mean, standard deviation)
2.6 3.0 3.5(3.0 ± 0.6) 2.5 3.0 3.5(2.9 ± 0.7) 2.5 3 3.4(2.9 ± 0.6) 0.02
Admission Diagnosis
Bronchiolitis 374 (31%) 129 (16%) 44 (16%) <0.01
Bronchopneumonia 476 (39%) 410 (52%) 134 (50%) <0.01
Pneumonia 225 (19%) 126 (16%) 43 (16%) 0.28
Suspected sepsis 150 (12%) 65 (8%) 33 (12%) 0.01
Pertussis-like cough 51 (4%) 16 (2%) 8 (3%) 0.03
Presenting symptoms
Fever 595 (49%) 463 (59%) 142 (53%) <0.01
Cough 1176 (97%) 685 (87%) 205 (76%) <0.01
Shortness of breath 964 (80%) 545 (69%) 175 (65%) <0.01
Runny nose/congestion 38 (3%) 17 (2%) 9 (3%) 0.38
Decrease appetite 234 (19%) 95 (12%) 47 (18%) <0.01
Seizures/convulsions 8 (1%) 19 (2%) 9 (3%) <0.01
Decrease activityd 45 (16%) 22 (12%) 18 (20%) 0.15
Diarrhea 58 (5%) 63 (8%) 17 (6%) 0.01
Vomiting 149 (12%) 97 (12%) 41 (15%) 0.39
Key  examination ﬁndings
Cyanosis 339 (28%) 150 (19%) 64 (24%) <0.01
Wheezing 926 (77%) 614 (78%) 217 (81%) 0.26
Flaring 173 (14%) 73 (9%) 35 (13%) 0.08
Abnormal x-raye 1076 (90%) 674 (89%) 222 (84%) 0.02
Outcomes
O2 requirementf 478 (40%) 248 (32%) 100 (38%) 0.002
Days  on oxygeng (25th, 50th, 75th,
mean, standard deviation)
1 2 5 (3.6 ± 3.3) 1 2 4 (3.3 ± 3.1) 1 2 3 (2.9 ± 3.1) 0.042
Mechanical ventilationsh 48 (4%) 31 (4%) 15 (6%) 0.46
ICU  stayh 107 (9%) 63 (8%) 40 (15%) 0.003
Median length of stay in daysi (25th,
50th, 75th, mean, standard
deviation)
2  3 6 (4.1 ± 3.3) 1 3 6 (4.2 ± 4.7) 1 3 6 (4.1 ± 4.3) 0.05
Deathh 7 (0.6%) 7 (0.9%) 7 (3%) 0.007
Vitamin D level (ng/mL)j 15.1 20.3 20.5 <0.01
a 2262.
b 2245.
c 2261.
d 553.
e 2216.
f 2239.
g
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h 2238.
i 2241.
j 1942.
eports typically fail to include information from the Middle East
egion due to lack of published data. Therefore, our study ﬁlls a
nowledge gap of RSV burden in the Arab region.
Our estimates of hospitalized RSV incidence are consistent
nd even slightly higher than other estimates from developed
nd developing counties in which RT-PCR was used to calcu-
ate RSV-associated hospital rates. For instance, our estimated
SV-associated hospitalization rates in children <6 months (range,
1–25 per 1000) were higher than a population-based study of
hree US hospitals that reported RSV-associated hospitalization
ates for children <6 months as averaging 17 per 1000 (range:
2.4–21.7) over a ﬁve-year period, in which 20% (564/2892) of the
ubjects were RSV-positive [44]. In a large population-based studyof ARI in Egypt, of the 4993 children <5 years of age in which a
specimen was collected, 518 (11%) of the children were positive
by RSV by RT-PCR, with the highest portion in the 1–11 months
group (45%). They estimated RSV-associated hospitalized rates in
children 1–11 months as 17.45 per 1000 [42]. Of note, they excluded
children <1 month of age, which most likely underestimated the
burden of RSV. Other studies that estimated population-based
RSV-associated hospital rates used less sensitive methods of RSV
detection or only included children with children with severe ARI
[45–48], making comparisons challenging. Our study highlights the
importance of active surveillance over longer study periods and
the advantage of sensitive molecular RSV detection techniques to
accurately estimate the true burden of RSV hospitalizations.
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Table  4
Univariate and multivariable analysis of factors associated with oxygen use, ICU stay, and mechanical ventilation in RSV-positive children.
Univariate analysis Multivariable analysis
Oxygen Use N = 1382 Oxygen N = 566 (%) No oxygen N = 816 (%) p-Value Adjusted OR (95% CI) p-Value 95% CI
Gender, male 321 (57%) 501 (61%) 0.08 1.21 0.15 0.94–1.56
Underlying medical condition 44 (8%) 63 (8%) 0.97 1.54 0.09 0.93–2.53
Daycare 13 (2%) 14 (2%) 0.44 1.52 0.38 0.60–3.86
Breastfeeding 482 (85%) 708 (87%) 0.40 0.60 0.01 0.40–0.89
Smoke exposure 428 (76%) 631 (77%) 0.46 1.14 0.39 0.85–1.53
Vitamin D level (ng/mL)a (25th,
50th, 75th, mean, standard
deviation)
2.9 10.7 23.6 (14.1 ± 12.4) 4.6 15.8 26 (16.6 ± 12.5) <0.01 0.89 0.67 0.69–1.15
Gestational age (weeks) (25th,
50th, 75th, mean, standard
deviation)
38 40 40 (38.5± 2.3) 38 40 40 (38.8± 2.2) 0.02 0.90 0.30 0.71–1.14
Median age, months [IQR] 2.3 4.8 <0.01 0.26 <0.01 0.18–0.40
RSV  ct count 24.9 26.4 <0.01 0.72 <0.01 0.59–0.87
Birth  Weight 3 3 0.77 1.12 0.37 0.88–1.42
Pneumonia 128 (23%) 96 (12%) <0.01 1.46 0.06 0.98–2.18
Bronchopneumonia 126 (22%) 342 (42%) <0.01 0.65 0.04 0.43–0.98
Bronchiolitis 151 (27%) 221 (27%) 0.87 0.64 0.03 0.43–0.98
Sepsis 128 (23%) 120 (15%) <0.01 0.57 0.01 0.37–0.86
Univariate analysis Multivariable analysis
ICU Stay N = 1381 ICU Stay N = 126 (%) No ICU Stay N = 1255 (%) p-value Adjusted OR (95% CI) p-value 95% CI
Gender, male 67 (53%) 754 (60%) 0.13 1.31 0.22 0.85–2.01
Underlying medical condition 12 (10%) 94(7%) 0.41 1.45 0.43 0.58–3.59
Daycare 0 (0%) 27 (2%) 0.10 NA NA NA
Breastfeeding 102 (81%) 1087 (87%) 0.08 0.55 0.08 0.28–1.07
Smoke exposure 93 (74%) 965 (77%) 0.44 1.01 0.98 0.61–1.67
Vitamin D level (ng/mL)b 9.7 14.5 0.13 0.85 0.73 0.53–1.36
Gestational age (weeks) 39 40 <0.01 0.76 0.06 0.50–1.15
Median age (months) [IQR] 1.5 3.7 <0.01 0.35 0.02 0.17–0.74
RSV  ct count 25.6 25.6 0.28 1.06 0.09 0.76–1.48
Birth  Weight 3 3 0.08 0.88 0.55 0.59–1.33
Pneumonia 45 (36%) 179 (14%) <0.01 1.89 0.02 1.11–3.20
Bronchopneumonia 12 (10%) 456 (36%) <0.01 0.38 0.03 0.16–0.90
Bronchiolitis 22 (17%) 350 (28%) 0.01 0.70 0.31 0.36–1.38
Sepsis 59 (47%) 189 (15%) <0.01 1.81 0.04 1.02–3.21
Univariate analysis Multivariable analysis
Mechanical ventilation (MV) N = 1381 MV N= 52 (%) No MV  N = 1329 (%) p-value Adjusted OR(95% CI) p-value 95% CI
Gender, male 29 (56%) 792 (60%) 0.58 1.09 0.78 0.61–1.95
Underlying medical condition 4 (8%) 102 (8%) 1 0.85 0.80 0.24–3.04
Daycare 2 (4%) 25 (2%) 0.32 3.09 0.15 0.66–14.52
Breastfeeding 45 (87%) 1144 (86%) 0.92 1.54 0.38 0.59–4.00
Smoke exposure 41 (79%) 1017 (77%) 0.7 0.72 0.37 0.35–1.49
Vitamin D level (ng/mL)b 20.5 13.9 0.19 1.94 0.06 1.06–3.57
Gestational age (weeks) 40 40 0.58 0.87 0.21 0.50–1.50
Median age, months [IQR] 2.5 3.6 0.02 0.29 0.03 0.11–0.77
RSV  ct count 26.8 25.6 0.53 1.25 0.39 0.77–2.05
Birth  Weight 3.05 3 0.76 1.52 0.14 0.87–2.67
Pneumonia 14 (27%) 210 (16%) 0.03 1.83 0.16 0.78–4.28
Bronchopneumonia 13 (25%) 455 (34%) 0.17 1.04 0.94 0.38–2.81
Bronchiolitis 14 (27%) 358 (27%) 1 0.96 0.92 0.39–2.35
 (18%)
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aSepsis 11 (21%) 237
a 1180.
b 1179.
Not only are the hospitalization rates of RSV-positive children
igher compared to RSV-negative, but the clinical characteristics
re different and the severity of illness seems to be greater in
hese children [14,44,49,50]. Prematurity and underlying med-
cal conditions (e.g., heart or lung disease) are well-recognized
isk factors for severe RSV [51]. However, the majority of our
SV-positive children were less likely to have been born pre-
aturely or have an underlying medical condition compared to
SV-negative, consistent with other studies [34,44]. In our cohort,
SV-positive children were more likely to be admitted with
vidence of lower respiratory involvement (e.g., higher frequency
f pneumonia, bronchiolitis and bronchopneumonia diagnoses
nd physical ﬁndings such as wheezing and retractions), present 0.54 0.65 0.34 0.27–1.57
with hypoxemia and cyanosis, and require supplemental oxygen
compared to RSV-negative children. Taken together, these results
suggest that RSV is more likely to cause severe infection compared
to other viruses.
Previously described risk factors associated with RSV hospital-
ization or severe illness include male sex, young age, birth in the
ﬁrst half of the RSV season, day care attendance, lack of breast
feeding, chronic medical conditions, smoke exposure, and house-
hold crowding or siblings [44,52–58]. Using oxygen use as on of
the indicators for severity, our results are consistent with other
reports ﬁnding a signiﬁcant higher odds ratios for oxygen use in
RSV-positive children with higher RSV viral load [59,60], lack of
breast feeding [61], and younger age [44]. When also evaluating
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Table 5
Multivariable analysis of Factors Associated with Length of Stay in RSV-Positive
Children.
Adjusted
OR (95% CI)
p-Value 95% CI
Gender, male 1.01 0.95 0.82–1.24
Underlying
medical
condition
1.63 0.02 1.10–2.42
Daycare 1.57 0.24 0.73–3.34
Breastfeeding 0.66 0.01 0.48–0.91
Smoke
exposure
0.99 0.94 0.78–1.25
Vitamin D level
(ng/mL)
0.97 0.64 0.78–1.19
Gestational age
(weeks)
0.92 0.04 0.76–1.11
Age@Enrollment 0.39 <0.01 0.28–0.55
RSV  ct count 0.68 <0.01 0.58–0.80
Birth Weight 0.87 0.16 0.71–1.05
Pneumonia 1.77 <0.01 1.27–2.46
Bronchopneumonia 0.71 0.04 0.51–0.99
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2007;53(3):179–84.Bronchiolitis 0.57 <0.01 0.41–0.79
Sepsis 2.08 <0.01 1.47–2.95
or ICU stay, mechanical ventilation, and length of stay, underlying
edical conditions [51] and the admission diagnoses of pneumonia
nd suspected sepsis were other risk factors identiﬁed. Environ-
ental tobacco smoke exposure is a known risk factor for serious
SV disease [62]. However, nearly 3/4 of our children were exposed
o smoke; this high exposure for the cohort may  explain why smoke
xposure was not identiﬁed as an independent risk factor. Low
itamin D levels and clinical rickets have been associated with
neumonia and severe ARI [63–66]. Low vitamin D levels were
ssociated with supplemental oxygen use in our univariate model;
owever, in the multivariable model it was no longer signiﬁcant.
herefore, further investigation and public health interventions to
educe modiﬁable risk factors such as vitamin D supplementation,
moking cessation programs, and encouraging breastfeeding are
eeded in our population.
Prevention of RSV disease in young children may  ultimately
e possible with active immunization or maternal immunization,
lthough no licensed RSV vaccine is currently available [67,68].
he only preventive measure for RSV disease is palivizumab, an
SV monoclonal antibody, which reduces the risk of hospitaliza-
ion caused by RSV in high-risk children [69]. Use of palivizumab
s low in low and middle income countries due to the high cost
f the drug. The vast majority of children hospitalized with RSV in
ur study were full term and previously healthy. Therefore, even if
alivizumab were available widely in Jordan, only a few children
ould have been eligible and thus it would have little impact on
verall RSV hospitalization rates. Other strategies to reduce RSV-
ssociated hospitalization are needed, such as infant or maternal
accination with future vaccines or antiviral therapies speciﬁc for
SV.
Our study is one of the largest prospective cohorts of Mid-
le East children hospitalized for ARI. Moreover, each subject had
olecular viral testing performed for 11 viruses and systematic
ata collection. However, our study does have some limitations.
he administration of oxygen and other treatments was  at the
linicians’ discretion and we only collected oxygen saturations at
dmission, so data may  not reﬂect truly serious disease. Never-
heless, RSV children were more likely to have lower saturation at
dmission compared to RSV-negative children, suggesting that RSV
s associated with increased morbidity. We  did not collect current
teroid use, except for inhaled steroids, prior or during admission,
hich may  have an effect on viral load and/or fever presentation.
hest radiograph ﬁndings were reported by clinicians and were not
[ (2015) 6479–6487
conﬁrmed by independent radiologists. Children who were classi-
ﬁed as virus-negative may  have had other viral infections that we
did not measure. Bacterial cultures were recorded when ordered by
clinicians, but their reliability was  uncertain because many infants
received antibiotics before admission (over 40%) and the micro-
biology laboratory is not open for 24 h, delaying the processing of
many specimens and therefore, we  are not able to comment reliably
about viral-bacterial co-infections. However, a recent prospective
US study found that the majority of LRTI in hospitalized young chil-
dren were caused by viral pathogens rather than bacteria (45). Since
our RSV samples are not genotyped, we  are unable to comment on
differences in severity between RSV A and RSV B.
In conclusion, our three years of rigorous hospital surveil-
lance conﬁrm that RSV is a major cause of illness in young
hospitalized Jordanian children. RSV is associated with
increased severity compared to other respiratory viruses. Children
in the Middle East would beneﬁt from an RSV vaccine if one
were available. In the meantime, public health policies directed
at encouraging breastfeeding could be immediate interventions.
RSV-speciﬁc chemotherapies are also needed. Future research
on judicious use of antibiotics and the role of viral-bacterial
co-detection are needed.
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